Skip to main content

Advertisement

SpringerLink
Log in

B cell-activating factor: its clinical significance in multiple myeloma patients

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

B cell-activating factor (BAFF) is a cytokine that plays a major role in the maintenance of normal B-cell development and homeostasis. It has been suggested that in multiple myeloma (MM) it might have regulatory effects on the proliferation and viability of malignant plasma cells. The aim of this study was to evaluate serum levels of BAFF in 52 newly diagnosed MM patients, with varying disease severity, in order to see the correlations between BAFF and indices of MM activity, such as interleukin-6, C-reactive protein, lactate dehydrogenase, and beta-2 microglobulin, and to explore the clinical significance of BAFF in predicting the disease activity of MM. We found increased BAFF serum levels in MM patients, increased in advanced stages, and decreased in plateau phase. We also found significant correlations between BAFF serum levels with the above parameters of disease activity. We conclude that BAFF may play an important role in pathogenesis of MM, could be used as a marker of disease activity, and a possible therapeutic target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Landgren O (2010) Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. Hematology Am Soc Hematol Educ Program 2010:295–302

    Article  PubMed  Google Scholar 

  2. Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K (2008) Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer 95:301–313

    PubMed  CAS  Google Scholar 

  3. Demchenko YN, Kuehl WM (2010) A critical role for NFκB pathway in multiple myeloma. Oncotarget 1:59–68

    PubMed  Google Scholar 

  4. Hanamura I, Stewart J, Huang Y, Zhan F, Santra M, Sawyer J, Hollnig K, Zangarri M, Pineda-Roman M, Van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108:1724–1732

    Article  PubMed  CAS  Google Scholar 

  5. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747–1756

    Article  PubMed  CAS  Google Scholar 

  6. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188:1185–1190

    Article  PubMed  CAS  Google Scholar 

  7. Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9:491–502

    Article  PubMed  CAS  Google Scholar 

  8. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS (2003) Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18:279–288

    Article  PubMed  CAS  Google Scholar 

  9. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108–2111

    Article  PubMed  CAS  Google Scholar 

  10. Treml JF, Hao Y, Stadanlick JE, Cancro MP (2009) The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53:1–16

    Article  PubMed  CAS  Google Scholar 

  11. Novak AJ, Bram RJ, Kay NE, Jelinek DF (2002) Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 100:2973–2979

    Article  PubMed  CAS  Google Scholar 

  12. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, Defrance T, Ajchenbaum-Cymbalista F, Simonin PY, Feldblum S, Kolb JP (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103:679–688

    Article  PubMed  CAS  Google Scholar 

  13. Briones J, Timmerman JM, Hilbert DM, Levy R (2002) BLyS and BLyS receptor expression in non-Hodgkin’s lymphoma. Exp Hematol 30:135–141

    Article  PubMed  CAS  Google Scholar 

  14. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103:689–694

    Article  PubMed  CAS  Google Scholar 

  15. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103:3148–3157

    Article  PubMed  CAS  Google Scholar 

  16. Jelinek DF, Darce JR (2005) Human B lymphocyte malignancies: exploitation of BlyS and APRIL and their receptors. Curr Dir Autoimmun 8:266–288

    Article  PubMed  CAS  Google Scholar 

  17. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66:6675–6682

    Article  PubMed  CAS  Google Scholar 

  18. Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, Tassone P, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N (2007) Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13:5903–5909

    Article  PubMed  CAS  Google Scholar 

  19. Ju S, Wang Y, Ni H, Wang X, Jiang P, Kong X, Zhong R (2009) Correlation of expression levels of BLyS and its receptors with multiple myeloma. Clin Biochem 42:387–399

    Article  PubMed  CAS  Google Scholar 

  20. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104–1112

    PubMed  CAS  Google Scholar 

  21. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104:607–618

    Article  PubMed  CAS  Google Scholar 

  22. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J, Rossi JF (2003) Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78:106–113

    Article  PubMed  CAS  Google Scholar 

  23. Hirano T (1998) Interleukin 6 and its receptor: ten years later. Int Rev Immunol 16:249–284

    Article  PubMed  CAS  Google Scholar 

  24. Nachbaur DM, Herold M, Maneschg A, Huber H (1991) Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 62:54–58

    Article  PubMed  CAS  Google Scholar 

  25. Lauta VM (2003) A review of the cytokine network in multiple myeloma. Cancer 97:2440–2452

    Article  PubMed  CAS  Google Scholar 

  26. Jiang P, Yueguo W, Huiming H, Hongxiang Y, Mei W, Ju S (2009) B-lymphocyte stimulator: a new biomarker for multiple myeloma. Eur J Haematol 82:267–276

    Article  PubMed  Google Scholar 

  27. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q (2007) Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12:252–265

    Article  PubMed  Google Scholar 

  28. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K, Dimopoulos MA, Greek Myeloma Study Group, Greece (2010) High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol 85:114–119

    PubMed  Google Scholar 

  29. Raje NS, Hohl Rj, Faber EA, Richardson PGG et al (2011) Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. J Clin Oncol 29, suppl; abstr 8012

  30. Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr (2008) Atacicept (TACI-Ig) inhibits growth of TACI (high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 22:406–413

    Article  PubMed  CAS  Google Scholar 

  31. Rossi JF, Moreaux J, Hose D, Requirand G, Rose M, Rouillé V, Nestorov I, Mordenti G, Goldschmidt H, Ythier A, Klein B (2009) Atacicept in relapsed/refractory multiple myeloma or active Waldenström’s macroglobulinemia: a phase I study. Br J Cancer 101:1051–1058

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, University Hospital of Heraklion, PO Box 1352, Heraklion, Crete, Greece

    M. Fragioudaki, G. Tsirakis, M. Spanoudakis & M. G. Alexandrakis

  2. Hematology Department, Venizelion General Hospital of Heraklion, Heraklion, Greece

    A. Boula & C. A. Pappa

  3. Hematology Laboratory, University Hospital of Heraklion, Heraklion, Greece

    F. Psarakis, I. S. Papadakis & M. G. Alexandrakis

Authors
  1. M. Fragioudaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Boula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Tsirakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Psarakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Spanoudakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. S. Papadakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. A. Pappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. G. Alexandrakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. G. Alexandrakis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fragioudaki, M., Boula, A., Tsirakis, G. et al. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann Hematol 91, 1413–1418 (2012). https://doi.org/10.1007/s00277-012-1470-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1470-x

Keywords

Search

Navigation